Teva Pharmaceutical Industries (TEVA) EBITDA Margin (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly EBITDA Margin came in at 5.58% in Q2 2026, down 1647.0% on a YoY basis from 0.36% in Q2 2025, and down 134.06% quarter-over-quarter from 16.37% in Q1 2026.
Powered by 
Analysis
Teva Pharmaceutical Industries (TEVA) EBITDA Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported EBITDA Margin for 18 consecutive years, with 5.58% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin fell 1647.0% year-over-year to 5.58%; the trailing twelve-month figure through Jun 2026 stood at 9.26% (up 341.0% YoY), and the FY2025 full-year result was 12.5%, up 1433.0% from the prior year.
- EBITDA Margin declined to 5.58% in Q2 2026 per TEVA's latest filing, from 16.37% in the prior quarter.
- Across five years, EBITDA Margin topped out at 19.69% in Q3 2025 and bottomed at 25.54% in Q2 2022.
- Historically, EBITDA Margin has averaged 0.24% across 5 years, with a median of 0.24% in 2023.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin plunged 4043 bps in 2022, then jumped 4116 bps in 2023.
- Over 5 years, EBITDA Margin stood at 24.2% in 2022, then surged by 170 bps to 16.96% in 2023, then tumbled by 106 bps to 1.0% in 2024, then surged by 737 bps to 6.37% in 2025, then slumped by 188 bps to 5.58% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 5.58%, 16.37%, and 6.37% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn | 25.95% |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | -134.08% |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 15.21% |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn | 9.72% |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.58% |
| Mar 31, 2026 | 16.37% |
| Dec 31, 2025 | 6.37% |
| Sep 30, 2025 | 19.69% |
| Jun 30, 2025 | 10.90% |
| Mar 31, 2025 | 13.34% |
| Dec 31, 2024 | -1.00% |
| Sep 30, 2024 | -1.18% |
| Jun 30, 2024 | -0.12% |
| Mar 31, 2024 | -5.71% |
| Dec 31, 2023 | 16.96% |
| Sep 30, 2023 | 8.94% |
| Jun 30, 2023 | -16.86% |
| Mar 31, 2023 | -0.36% |
| Dec 31, 2022 | -24.20% |
| Sep 30, 2022 | 11.79% |
| Jun 30, 2022 | -25.54% |
| Mar 31, 2022 | -19.48% |
| Dec 31, 2021 | 1.90% |
| Sep 30, 2021 | 16.03% |